
hVIVO
hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

ichorbio
ichorbio is a manufacturer of bulk in vivo antibodies and research biosimilars based in Oxford, United Kingdom.
At ichorbio, their vision is to develop the highest quality reagents to advance scientific research and progress. They believe that the excellence of our products directly impacts the meaningfulness of research outcomes.
As a boutique reagent manufacturer, their target customers are scientists seeking reliable antibodies and other research tools. They aim to provide these products at fair prices - keeping our focus on customers, not shareholders.
Thier best selling in vivo products include RMP1-14, 10F.9G2 and 2.43. Their best selling research biosimilars include mosunetuzumab, odronextamab and aflibercept. Their best selling isotype controls include Rat IgG2a isotype control, Rat IgG2b isotype control, Human IgG1 isotype control and Human IgG4 S228P isotype control.